Recurrent gefitinib-induced interstitial lung disease

Internal Medicine

Volumn 47, Issue 6, 2008, Pages 533-536

  Suzuki, Masaru ^a   Asahina, Hajime ^a   Konishi, Jun ^a   Yamazaki, Koichi ^a   Nishimura, Masaharu ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Drug induced lung injury; Epidermal growth factor tyrosine kinase; Gefitinib; Non small cell lung cancer

Indexed keywords

CARBOPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; METHYLPREDNISOLONE; PACLITAXEL; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE;

ADULT; ANAMNESIS; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FEVER; HOSPITAL ADMISSION; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG ADENOCARCINOMA; LYMPH NODE METASTASIS; MALE; MEDIASTINUM METASTASIS; MEDIASTINUM TUMOR; THROMBOCYTOPENIA; CHEMICALLY INDUCED DISORDER; LUNG; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MIDDLE AGED; PATHOLOGY; RADIOGRAPHY; RECURRENT DISEASE;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG; LUNG DISEASES, INTERSTITIAL; LUNG NEOPLASMS; MALE; MIDDLE AGED; QUINAZOLINES; RECURRENCE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 41649089408     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.47.0737     Document Type: Article

References (9)

1. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 21: 2237-2246, 2003.
2. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. a randomized trial. JAMA 290: 2149-2158, 2003.
3. Ieki R, Saitoh E, Shibuya M. Acute lung injury as a possible adverse drug reaction related to gefifinib. Eur Respir J 22: 179-181, 2003.
4. Inoue A, Saijo Y, Maemondo M, et al. Severe acute interstitial pneumonia and gefifinib. Lancet 361: 137-139, 2003.
5. Okamoto I. Fujii K, Matsumoto M, et al. Diffuse alveolar damage after ZD1839 therapy in a patient with non-small cell lung cancer. Lung Cancer 40: 339-342, 2003.
6. Kudoh S, Kato H, Nishiwaki Y, et al. A cohort and nested case-control study to quantify the risk of interstitial lung disease (ILD) in Japanese patients with NSCLC treated with gefitinib or chemotherapy. Am J Respir Crit Care Med 175: A148, 2007 (Abstract).
7. Camus P. Drug-induced infiltrative lung diseases. In: Interstitial Lung Disease. 4th ed. Schwartz MI, King Jr TE, Eds. BC Decker Inc, Hamilton, 2003: 485-534.
8. Inomata. S, Takahashi H, Nagata M, et al. Acute lung injury as an, adverse event of gefitinib. Anticancer Drugs 15: 461-467, 2004.
9. Kitajima H, Takahashi H, Harada K, et al. Gefitinib-induced interstitial lung disease showing improvement after cessation: disassociation of serum markers. Respiratory 11: 217-220, 2006.